Intrarosa/prasterone Cost, Side effects, Dosage, Uses for intercourse Pain in Women

Intrarosa is marketed by Quebec-based Endoceutics Inc.

U.S. FDA approved a new product Intrarosa that contains active ingredient prasterone for the treatment of pain in postmenopausal women during sexual intercourse. This pain intensity might be moderate to severe and condition is known as dyspareunia. Intrarosa is first kind of this category approved by FDA. Prosterone is basically a steroidal hormone that produces naturally inside body ( endogenous Production). It is also know as Dehydroepiandrosterone (DHEA) and circulates in human body in large amounts. Prosterone plays many physiological role in the body like biosynthesis of sex hormones like estrogens and androgens.

Postmenopuasal problems are very common in women like flushing, mood swings, metabolic changes in the body and osteoporosis. According to research major underlying cause of intense pain during sexual intercourse in postmenopausal women is atrophy of internal membrane of vulva and vagina. It is proposed that this atrophy is triggered due to low levels of estrogen circulating in the body and vaginal tissues for a long time and condition is known as vulvar and vaginal atrophy (VVA).

Basic mechanism of Intrarosa (prasterone) is that it decreases the adrenal insufficiency in women but still exact pathway by which it works is not fully understood due to inadequate clinical data. According to FDA its efficacy was established after 12 week clinical trials and women who were taking intrarosa during these trials experienced remarkable decrease in the severity of pain.


Intrarosa/prasterone Side effects 

According to data obtained from clinical trials all side effects were minor to moderate. During these clinical trials no life threatening or lethal side effect was reported. Detail of these side effects is as follows

Minor Side effects

  • Headache
  • Irritation during insertion
  • Sense of discomfort in lower abdominal

Moderate Side effects

  • Vaginal Discharge
  • Abnormal Pap smear
  • Vaginal pain
  • Vaginal odor

Intrarosa/prasterone Uses or Prescribing Information

Though, prasterone is available in many dietary supplements but FDA approved only vaginal pessaries of prasterone to decrease the intensity of pain during intercourse in postmenopausal women. According to clinical trials intrarosa shows its therapeutic effect when used for specified period of time. Short term usage for few days does not produce significant effect.

Intrarosa/prasterone Cost and Dosage

This drug is presented to FDA as vaginally inserted dosage form but it’s potency and dosage frequency is difficult to evaluate until it appears in the market. So, we will update all the parameters of this drug once, it gets available in the market.

Lartruvo/olaratumab Cost, Side effects, Dosage, Uses for soft tissue sarcoma (STS)

Lartruvo is marketed by Eli Lilly and Company based in Indianapolis, Indiana.


FDA has approved a new drug Lartruvo for soft tissue sarcoma. This drugs contains active ingredient olaratumab which monoclonal antibody and extracted from human origin.Monoclonal antibodies are derived from cells of immune system and have high affinity for binding to specific site. Monoclonal antibodies are commonly usedin chemotherapy to target specific site and minimize the chances of toxicity.

FDA recommended the usage of newly approved drug Lartruvo (olaratumab) in combination with doxorubicin to make soft tissue sarcoma treatment more effective.According to guidelines provided by FDA this drug along with doxorubicin should only be used in those patients who are not recovering after radiation or surgery.

Soft tissue sarcoma (STC) is a kind of tumor that originates from connective tissues. There are number of underlying factors that contribute towards development of soft tissue sarcoma. For example excessive exposure to toxic substances in chemical industries, severe viral infection, genetic predisposition, environmental exposure or pollution etc.

Basic mechanism of Lartruvo (olaratumab) is that it blocks platelet derived growth factor (PDGF) receptor alpha that increases the growth of soft tissue sarcoma. PDGF is basically a protein that contributes in tumor growth. Latruvo decreases the progression of this disease by blocking these proteins.


Lartruvo/olaratumab Cost, Side effects, Dosage, Uses for soft tissue sarcoma (STS)


Lartruvo/olaratumab Side effects

According to data received from clinical trails following side effects were observed initially,

  • Neuropathy or Nerve damage
  • Baldness
  • Loss of appetite
  • Low white blood cells count (Neutropenia)
  • Fetal abnormalities
  • Reactions during infusion
  • Blood pressure fluctuations
  • Asthenia
  • Swelling of mucous membranes
  • Headache
  • Musculoskeletal pain
  • Nausea
  • Vomiting
  • Abdominal discomfort

Lartruvo/olaratumab prescribing information/uses

According to data provided by U.S FDA this drug is reserved for those patients who are not responding to radiations or surgery. FDA also recommended that this drug should be used in combination with doxorubicin to make the treatment more targeted and effective.

Lartruvo/olaratumab Dosage

This drug is formulated as a 50ml vial for intravenous use with potency of 10mg/ml. Standard dosage of lartruvo for the treatment of soft tissue sarcoma is 15mg/Kg intravenously at rate of 1-8hrs.Dose adjustment can be done depending upon the patient condition and disease progression.

Lartruvo/olaratumab Cost

According to market survey this drug is currently not available at retail outlets because it is recently approved by FDA via accelerated approval pathway. It means FDA may ask for further investigational study and research regarding its clinical efficacy, safety, drug profile, pharmacokinetics and pharmacodynamics.Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Amjevita/adalimumab-atto Cost, Side effects, Dosage, Uses for multiple inflammatory diseases

Amjevita is manufactured by Amgen, Inc., of Thousand Oaks, California.

The U.S. Food and Drug Administration has approved a new biosimilar drug Amjevita that contains adalimumab-atto as an active pharmaceutical ingredient.Amjevita is a biosimilar to previously approved drug Humira manufactured by AbbVie Inc. of North Chicago, Illinois.

   
Amjevita/adalimumab-atto basic mechanism is inhibition or suppression tumor necrosis factor alpha (TNFa) which is main culprit for inflammatory response in inflammatory diseases (auto-immune) like rheumatoid arthritis, psoriatric arthritis, ankylosing spondylitis etc.It was observed during clinical trial that administration of adalimumab and methotrexate (MTX) provide synergistic effect and doubles the therapeutic efficacy of methotrexate. Apart from these indications Amjevita/adalimumab-atto can also be used in a patho-physiological condition where suppression of immune system is required. This drug is administered through subcutaneous route (sc).

Multiple inflammatory diseases is a group of disorders that belongs to malfunctioning of immune system. Most common examples of these diseases are rheumatoid arthritis, ulcerative colitis, crohn's disease, hidradenitis suppurativa, juvenile idiopathic arthritis. All kinds of auto-immune disorders are treated and managed by following combination of therapy like DMARD's, Immunosuppressants, Steroidal drugs, etc.

Amjevita/adalimumab-atto Cost, Side effects, Dosage, Uses for multiple inflammatory diseases

 Amjevita/adalimumab-atto Side effects


Amjevita is a biosimilar of Humira  so, both have almost same kind of indications and side effects. These side effects can be categorized into moderate to severe.

Moderate Side effects 

  • Generalized weakness
  • feeling of numbness
  • Body pain
  • Shortness of breath
  • vision problems
  • skin rashes
  • swelling on body

Severe Side effects

Severe kind of side effects associated with this drugs are increase risk of

  • Infections like respiratory infection, liver and kidney infection.
  • Malignancy  

Amjevita/adalimumab-atto Uses

U.S FDA approved this drug for multiple inflammatory diseases which is a class of auto-immune disorders. Auto-immune disorders are of many types like rheumatoid arthritis, ulcerative colitis, crohn's disease, hidradenitis suppurativa, juvenile idiopathic arthritis. This drug can also be used in combination with other drugs like methotrexate.

Amjevita/adalimumab-atto Dosage

This drug is formulated as pre-filled syringe with potency of 40mg/0.8ml. Standard dosage of amevita/adalimumab  is 40mg after every two weeks. It is administered subcutaneously and dose may be adjusted depending upon the severity of disease and patient condition. During this therapy your health care provider may also prescribe you some other DMARD's like methotrexate to make the treatment more effective.

Amjevita/adalimumab-atto Cost 

According to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Exondys 51/eteplirsen Cost, side effects, Mechanism, Dosage for Duchenne muscular dystrophy (DMD)

Exondys 51 is made by Sarepta Therapeutics of Cambridge, Massachusetts.

US FDA approved a new novel drug Exondys 51 for the treatment of Duchenne muscular dystrophy (DMD). This drug contains eteplirsen as an active ingredient. Exondys 51/eteplirsen specifically targets mutations that occurs in DMD gene.This drug has been approved only for the treatment and management of Duchenne muscular dystrophy (DMD) but it does not mean that it cures it forever.

Duchenne muscular dystrophy (DMD) is rare kind of disorder but it is very devastating degenerative disease. In this disease some mutational changes occur in DMD gene which leads to alteration in DMD RNA transcription process. This altered DMD RNA becomes non-functional or in-active and does not bind or recognize dystrophin protein. This is the main root cause of Duchenne muscular dystrophy (DMD).

Exondys 51/eteplirsen Mechanism of Action or Pharmacology


Exondys 51/eteplirsen is  morpholino antisense oligomer that causes cleavage of exon 51 (part of a gene that will encode a part of the final mature RNA) during pre mRNA splicing phase of dystrophin protein.This process will generate a functional but modified form of dystrophin protein (skipping exon therapeutically) that can reinstate the binding process that was impaired due to genetic mutations.

The whole process initiated by this drug does not cure this problem but reduce the severity, progression and degeneration. Majority of patients suffering from DMD have this kind of mutation and can be treated effectively with the help of this therapeutic drug Exondys 51/eteplirsen.

Exondys 51/eteplirsen Cost, side effects, Mechanism, Dosage for Duchenne muscular dystrophy (DMD)


Exondys 51/eteplirsen Side effects

According to clinical trials this drug exhibited some minor side effects but no life threatening side effect was reported at that time. These minor side effects were

  • Balance disorder
  • Nausea
  • Vomiting
  • Headache
  • Dizziness
  • palpitation

This drug is administered in form of infusion through intra-venous route only.

Exondys 51/eteplirsen Dosage

This drug is formulated as a single dose vial with potency of 50mg/ml. In adult DMD patients  its standard dosage is 30mg/Kg through intravenous route once in a week. Dose titration may be considered depending upon the patient condition and severity of disease. 

Exondys 51/eteplirsen Cost

This drug is administered by your healthcare practitioner (HCP), which usually means:
  • It may comes under special items category.
  • You cannot fill this prescription in a regular pharmacy. Your doctor, hospital, or clinic will provide this  medication because of possible complications or other issues.
  • This drug is likely to be covered under your medical benefit if you have insurance.

Erelzi Cost, Side effects, Uses, Dosage for Multiple Inflammatory Diseases

Erelzi is manufactured by Sandoz Inc., based in Princeton, New Jersey, at Novartis Pharma in Stein, Switzerland.

US Food and Drug Administration approved a new bio-similar drug Erelzi that contains active ingredient etanercept-szzs for the treatment of multiple inflammatory disease. Multiple Inflammatory disease includes rheumatoid arthritis (RA) which is swelling of joints and periphery tissues along with inflammation, systemic lupus erythematosus (SLE) which causes inflammation and swelling of skin, joints, kidneys, brain, and other organs and metabolic system disease like celiac sprue disease in which intestine produces inflammatory response upon gluten (barley, rye and wheat) intake that causes damage to the lining of the small intestine.

Erelzi can be used in combination with DMARD's ( disease modifying anti-rheumatic drugs) like methotrexate for the treatment of psoriatic arthritis, ankylosing spondylitis, plaque psoriasis and other auto-immune disorders. Erelzi should be used with caution because it may increase the risk of infections like T.B (tuberculosis), histoplasmosis, live and kidney disease. Erelzi should be used only in case where no appropriate alternative is available because etanercept containing products may increase the risk of malignancy upon prolong intake. Erelzi should not be administered to patients with sepsis.


Erelzi Cost, Side effects, Uses, Dosage for Multiple Inflammatory Diseases
Erelzi Cost, Side effects, Uses, Dosage for Multiple Inflammatory Diseases

 Erelzi Side effects

During clinical trials Erelzi shows some side effects that were moderate to severe. There side effects are

Moderate Side effects


  • Rashes
  • Nausea
  • Vomiting
  • Dyspepsia
  • Abdominal pain
  • Fatigue

Severe Side effects

  • Increased risk of malignancy
  • Increased risk of tuberculosis
  • Increased risk of fungal infection (histoplasmosis)
  • Increased risk of sepsis. 

Erelzi Prescribing information or Uses


U.S FDA approved Erelzi for severe kind of multiple inflammatory disease like rheumatoid arthritis, Plaque arthritis, idiopathic juvenile arthritis, ankylosing spondylitis and other auto-immune diseases in combination with some other suitable agents like DMARD's.

Erelzi  Dosage

Standard dose of erelzi is 25mg two times in a week or 50mg once in a week. This drug is administered through subcutaneous route. If your doctor has prescribed  it you twice in a week then maintain a gap of 3-4 days between two consecutive doses. This drug may also be used in combination with other drugs like glucocorticoids,  methotrexate and NSAIDs.

Erelzi Cost 


According to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Adlyxin/lixisenatide Cost, Side effects, Dosage, Uses for Type 2 Diabetes

Adlyxin is manufactured by Sanofi-Aventis U.S. LLC, of Bridgewater, New Jersey.

Adlyxin with an active ingredient lixisenatide is the new drug approved by U.S. Food and Drug Administration on July 28, 2016. This drug is approved in parentral dosage form. It's dosage frequency is once a day and injected through subcutaneous route. Adlyxin/lixisenatide belongs to a class of drug called as a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is hormone that helps in the regulation of blood sugar control.

Type 2 diabetes is a common problem in US population. In type 2 diabetes, insulin produces at normal level but insulin sensing receptors present in liver, kidney and other organ tissues become desensitize. This desensitization leads to improper or poor attachment of insulin at insulin bind receptors. Ultimately, patient loses his control over blood sugar and becomes diabetic.

Adlyxin is aimed to improve blood  sugar level along with exercise and dietary control because no single pill can efficiently control blood sugar control without taking further measures. Type 2 diabetes is a kind of disease that can be managed by taking medications along with life style modifications.

During clinical trails Adlyxin safety profile was quite satisfactory. Adlyxin is quite safe for patient having types 2 diabetes along with atheroseclerosis ( stenosis of arteries).  Adlyxin helps to improve blood sugar level with no harm to cardiac issues like angina, atrial fibrillation, tachycardia, thromboembolic phenomenon and atherosclerosis.

Adlyxin/lixisenatide Cost, Side effects, Dosage, Uses for Type 2 Diabetes


Adlyxin/lixisenatide Side effects


Adlyxin was tested for possible side effects during clinical trials. These side effects were mild moderate.
  • Nausea
  • Vomiting
  • Headache
  • Diarrhea
  • Dizziness
  • Hypersensitivity
  • Anaphylaxis
  • Asthenia
  • Muscle Weakness
  • Mild Fever
  • Rash at injection site
  • Loss of appetite 
 According to data received from clinical trials, Adlyxin does not have life threatening or lethal side effects.


 Adlyxin/lixisenatide Uses/Prescribing Information 

US FDA approved Adlyxin to control blood sugar level in type 2 diabetes. Adlyxin gives better control over blood sugar level if it used with other diabetes medications following life style modifications and dietary restrictions.

However, this drug was also tested as standalone therapy during clinical trials in which it is showed promising results. Adlyxin should not be used to treat people with type 1 diabetes or patients with increased ketones in their blood or urine (diabetic ketoacidosis).

 Adlyxin/lixisenatide Dosage

Adlyxin/lixisenatide pack contains two types of pen. One is green pen and other is bugendy pen. Green pen is 3mL prefilled pen and each ml contains 50mcg/ml dose. It is used as starter dose. It provides 14 dose of 10mcg/dose. Start with green pen and inject subcutaneously 10mcg/day for 14 days.

Now, on day 15 use burgundy pen as maintenance dose. Burgundy pen is also 3mL prefilled pen and each ml contains 100mcg/ml dose. It is used as maintenance dose. It provides 14 doses of 20mcg/dose. Inject subcutaneously 20mcg/day for 14 days.

 Adlyxin/lixisenatide Cost 

According to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Xiidra/lifitegrast Cost, Side effects, Dosage, Uses for Dry eye

Xiidra is manufactured by Shire US Inc., of Lexington, Massachusetts.

FDA has approved a new drug having active ingredient lifitegrast with brand name of Xiidra for the treatment of dry eye disease. This drug belongs to class termed as lymphocyte function-associated antigen 1 (LFA-1) antagonist. This is first kind of drug of its class approved for the treatment of dry eye disease. This drug is presented to FDA in the form of ophthalmic solution and marked as prescription only medicine.

Dryness of eyes is a common problem in elder people due to decrease activity of tears gland. Dryness of eye itself does cause any harm or damage to eye but it increases the risk of eye ulcer, corneal injury, difficulty in blinking, vision problem etc. About 5% of individuals having age 30 to 40 years have problem of dryness of eyes while people with age more than 65 years have 10% occurrence rate.

Most common reasons of eye dryness is inadequate production of tears or low consistency of ophthalmic fluid. These problem may arise due to extreme weather conditions like extreme hot or cold weather or too much air pressure.

About 1100 individuals were selected to assess the clinical efficacy and safety profile of Xiidra/lifitegrast. It shows satisfactory results in four randomized controlled clinical trials. During these clinical trials patients received lifitegrast eyedrops or placebo eyedrops twice daily 12 hours apart for 12 weeks.

 Xiidra/lifitegrast Cost, Side effects, Dosage, Uses for Dry eye


Xiidra/lifitegrast Side Effects

During clinical trials most common side effects observed were mild to moderate but there was no evidence of serious kind of side effects. Some common side effects were

  • Eye irritation
  • Blurred vision
  • Discomfort
  • Dysgeusia (Feeling unusual taste)
  • Headache
  • Burning sensation

Xiidra/lifitegrast Uses or Prescribing Information

FDA approved Xiidra/lifitegrast for treatment of dryness of eye in ophthalmic dosage form. Tin his drug is marked as prescription only medicine so you need a valid prescription in order to get this medicine.

Xiidra/lifitegrast Cost

This drug was presented to FDA in ophthalmic dosage form with potency of  5% ophthalmic solution. Xiidra is now available in market with pack size of 60's. According to market survey initial cost of one box is about 400$ - 500$ that contains 60 ampules. This approximate cost may variate with the passage of time so, we will update you accordingly.

Xiidra/lifitegrast Dosage

In adults, usual dosage frequency of xiidra is one drop into each eye after every 12hrs for 3-5 days depending upon the severity of disease. In children, xiidra safety profile has not yet evaluated.

Epclusa Cost, Side effects, Dosage, Uses for Hepatitis C infection

Epclusa is manufactured and marketed by Gilead Sciences, Inc., of Foster City, California.

Epclusa  is first kind drug approved by US FDA for the treatment of all six major HCV genotypes. Epclusa contains combination of sofosbuvir, a drug approved by FDA as break through therapy for HCV and  velpatasvir, a new drug, and is the first to treat all six major forms of HCV.

US FDA approved this drug on July 28 2016 for the treatment of chronic type of hepatitis in adult patients with cirrhosis or without cirrhosis. If liver cirrhosis progresses to advance stage then Epclusa is used with antiviral drug called as ribavirin.

Hepatitis C is a viral infection leads towards liver cirrhosis if it persists for a long term. HCV virus has 6 genotypes 1 to 6. Each genotype requires duration of therapy and in some cases therapy may also be changed. In United States about 75% people have genotype 1 that means genotype 1 is the most common type in United States of America. Genotype 2 has prevalence rate of 25%. Other genotypes are less common and only few patients are diagnosed with such kind of genotypes.

Epclusa Cost, Side effects, Dosage, Uses for Hepatitis C infection
Epclusa Cost, Side effects, Dosage, Uses for Hepatitis C infection


Epclusa Side effects


There are two types of side effects that were observed during Epclusa clinical trials like moderate and severe type of side effects.

Moderate Side effects include  
  • Fatigue
  • Headache
  • Nausea 
  • Vomiting
  • Dizziness
  • Dry Cough
  • Fever
  • Myalgia
  • Stomach discomfort
  • Dryness
Severe Side effects include

  • Bradycardia 
  • Hypersensitivity
  • Cardiac arrhythmia 
Epclusa may interact with some other drugs for example it should not be used with amiodarone due to increase cardiac risks like rapid fluctuations in heart rate, severe bradycardia and cardiac arrest. Some drugs may reduce the serum level of epclusa which will reduce the efficacy of drug.

Epclusa Uses or Prescribing Information


Epclusa is prescribed for the treatment of chronic HCV infection in adults having liver cirrhosis or do not have liver cirrhosis. It indicated for all kinds of HCV genotypes because it contains combination of drugs. Up-till now, Epclusa is only regimen to treat all six major HCV genotypes effectively.

Epclusa Cost


This drug is presented to FDA in tablet form (oral dosage form) with potency 400mg/100mg (Sofosbuvir 400mg and velpatasvir 100mg). According to market survey price of epclusa is variable but approximate average cost of one pack of epclusa ranges between 24,000$ - 26,000$. One pack of epclusa contains 28 tablets ( 28's pack size).  This approximate cost may also variate with the passage of time so, we will update you accordingly.

Epclusa Dosage

This drug is indicated for chronic hepatitis C in adults with genotype 1,2,3,4,5 and 6. According to clinical data provided by health authorities the dosage frequency is once a day through oral route (PO). Duration of therapy depends upon patient liver condition and genotype. However, average duration of therapy is between 4-6 months. This drug my be used in combination with other antiviral drugs for targeted therapy.

Ocaliva/obeticholic acid Cost, Side effects, Dosage, Uses in primary biliary cholangitis

Ocaliva is manufactured by New York, New York-based Intercept Pharmaceuticals, Inc.

Food and Drug Administration has approved Ocaliva that contains active ingredient obeticholic acid for the treatment of primary biliary cholangitis (PBC). FDA proposed this drug  to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to ursodeoxycholic acid, or as a single therapy in adults unable to tolerate UDCA.

Ocaliva, given orally, ties to the farnesoid X receptor (FXR), a receptor found in the core of cells in the liver and digestive system. FXR is a key controller of hepatic metabolic pathways. Ocaliva expands bile stream from the liver and stifles bile acid creation in the liver, in this way decreasing the exposure of the liver to lethal levels of biliary contents.

PBC is an chronic, or long lasting, illness that causes blockage of biliary system in the liver to end up kindled, harmed and at last pulverized. This causes bile to stay in the liver, which harms the liver cells after some time, and results in cirrhosis, or scarring of the liver. As cirrhosis advances, and the measure of scar tissue in the liver expands, the liver loses its capacity to work.
Ocaliva/obeticholic acid Cost, Side effects, Dosage, Uses in primary biliary cholangitis
Ocaliva/obeticholic acid Cost, Side effects, Dosage, Uses in primary biliary cholangitis

Ocaliva Side effects

The most common side effects of Ocaliva are

  • Pain in the middle part of the throat (oropharyngeal)
  • Severe itching of the skin (pruritus)
  • Abdominal pain and discomfort
  • Generalized weakness
  • Joint pain (arthralgia)
  • Fatigue
  • Dizziness
  • Constipation
  • Headache
  • Mild fever

Ocaliva should not be used in patients with complete biliary obstruction.

Ocaliva Uses or Prescribing information 

Patients left untreated, or who have not reacted to ursodeoxycholic acid, are at danger for liver cirrhosis and death. Ocaliva gives a vital treatment choice to patients living with initial biliary cholangitis who have not responded to the main other affirmed treatment, ursodeoxycholic acid.

Ocaliva is reserved for the treatment of initial biliary cholangitis in combination with ursodeoxycholic acid in grown-ups with a deficient response to ursodeoxycholic acid, or as a solitary treatment in grown-ups not able to endure ursodeoxycholic acid.

Ocaliva Cost

According to market survey average cost of 30 ocaliva tablets with potency of 5mg is approximately 5840$ to 5890$. Similarly 30 ocaliva talets with potency of 10mg is approximately 6000$ to 6250$. This cost may vary due to number of factors like location, discount policy or coupon system. Ocaliva is now available in two pack size 30's and 90's.

Ocaliva Dosage

Ocaliva is available in two potencies 5mg and 10mg. Usual dose of ocaliva at startup is 5mg orally every day. If it does not give adequate response after taking 2-3 weeks then dose may titerate up-to 10mg once a day. Dose should not be exceed 10mg/day.

Zinbryta/daclizumab Cost, Side effects, Uses, Dosage for multiple sclerosis

Zinbryta is manufactured by Biogen, Inc. of Cambridge, Massachusetts.

The U.S. Food and Drug Administration has been approved Zinbryta that contains active ingredient daclizumab for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta belongs to a class termed as monoclonal antibodies. Zinbryta is presented in parentral dosage form and categorized as long acting agent.

Zinbryta should be reserved for  those patients who have had a deficient response to combination therapy for multiple sclerosis (MS) on the grounds that Zinbryta has genuine dangers including liver damaging effects and modulation of immune system. In light of the dangers, Zinbryta has a boxed cautioning and is accessible just through a limited circulation program under a risk Evaluation and mitigation Strategy.

MS is a chronic, provocative, immune system malady of the focal sensory system that disturbs the co-ordination between the spinal region and different parts of the body. It is among the most widely recognized reasons for neurological disability in adults and happens more often in ladies than men. For the vast majority with MS, episodes of worsening function (relapses) are initially followed by recovery periods (remissions).


Zinbryta Side effects

The most common adverse reactions that wrere observed during Zinbryta therapy are
  • Cold symptoms (nasopharyngitis)
  •  Increased alanine aminotransferase
  • Throat (oropharyngeal) pain
  • Enlargement of lymph nodes
  • Upper respiratory tract infection
  • Rash
  • Influenza
  • Dermatitis
  • Eczema
  • Depression

 Zinbryta Uses or prescribing information

Due to serious side effects produced by Zinbryta it should be reserved for those patients who have had a deficient response to combination therapy for multiple sclerosis (MS) or relapsing forms of multiple sclerosis (MS)

The viability of Zinbryta was appeared in two clinical trials. One trial conducted at Zinbryta and Avonex in 1,841 members who were studied for 144 weeks. Patients on Zinbryta had less relapses than patients taking Avonex.

The second trial was conducted between Zinbryta and inactive agent (placebo) and included 412 members who were dealt with for 52 weeks. In that study, those accepting Zinbryta had less relapses as compared with those getting inactive agent.

Zinbryta Cost

This drug is now available in market in a single-dose prefilled syringe with potency of 150mg/ml. According to market survey initial price of a single-dose prefilled syringe of zinbryta costs about 7000$ - 7600$. This approximate cost may variate with the passage of time so, we will update you accordingly.

Zinbryta Dosage

In adults, usual dosage frequency of zinbryta is 150mg subcutaneously (SC) once in a month in case of recurrent episodes of multiple sclerosis. Dose titration may be required in case of liver impairment. In children, safety profile of zinbryta/daclizumab has not yet evaluated.